Results 111 to 120 of about 122,944 (342)

FGL2‐HDAC11 Drives Immunothrombosis via NETs‐Mediated Endothelial Capillarization in MASLD Fibrosis

open access: yesAdvanced Science, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is frequently accompanied by hepatic fibrosis and systemic cardiovascular complications; however, the mechanistic interplay between coagulation abnormalities and disease progression remains poorly defined.
Xitang Li   +16 more
wiley   +1 more source

Discovery and structural characterisation of new fold type IV-transaminases exemplify the diversity of this enzyme fold

open access: yesScientific Reports, 2016
Transaminases are useful biocatalysts for the production of amino acids and chiral amines as intermediates for a broad range of drugs and fine chemicals.
T. Pavkov-Keller   +8 more
semanticscholar   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

open access: yesAdvanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee   +6 more
wiley   +1 more source

Discovery of biophysical rate laws from the electronic health record enables real-time liver injury estimation from transaminase dynamics

open access: yesCell Reports Medicine
Summary: Alanine (ALT) and aspartate (AST) aminotransferases are standard-of-care biomarkers for liver injury though their temporal dynamics during injury and resolution remain incompletely characterized.
Marc S. Sherman, Wolfram Goessling
doaj   +1 more source

Amine Transaminases in Multi-Step One-Pot Reactions

open access: yes, 2017
Amine transaminases are enzymes that catalyze the mild and selective formation of primary amines, which are useful building blocks for biologically active compounds and natural products.
Anderson, Mattias
core  

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

open access: yesAdvanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong   +8 more
wiley   +1 more source

Liver dysfunction in steady state sickle cell disease

open access: yesAnnals of Hepatology, 2005
The Liver is one of the organs involved in the multiorgan failure that occurs in sickle cell disease, the pathophsiology of liver disease in this condition is complex because of the interrelated multifactorial causes.
Taiwo Kotila   +5 more
doaj   +1 more source

A metagenomics approach for new biocatalyst discovery: application to transaminases and the synthesis of allylic amines

open access: yes, 2017
Transaminase enzymes have significant potential for the sustainable synthesis of amines using mild aqueous reaction conditions. Here a metagenomics mining strategy has been used for new transaminase enzyme discovery.
D. Baud   +4 more
semanticscholar   +1 more source

Serum Transaminases in 60 Asymptomatic Obese Women [PDF]

open access: yes, 2009
INTRODUCTION : Now that routine laboratory testing is automated and is frequently part of an annual health check up plans, physicians are often faced with the problem of a patient with one abnormal result on the measurement of serum Aminotransferases ...
Mahadevan, G R
core  

Microglia‐Targeted Biomimetic Tetrahedral Framework Nucleic Acid Nanovesicles for Synergistic Treatment of Sepsis‐Associated Encephalopathy

open access: yesAdvanced Science, EarlyView.
Sepsis‐associated encephalopathy (SAE) lacks effective therapies. We developed ME@FDsi, a biomimetic nanodrug using a tetrahedral framework nucleic acid to deliver disulfiram and siTNFα. It crosses the blood‐brain barrier, targets M1 microglia, inhibits pyroptosis and inflammation, and scavenges ROS.
Huimin Shi   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy